Sign in

    Richard Fellinger

    Research Analyst at Autonomous Research

    Richard Fellinger is Vice President and Senior Research Associate at Autonomous Research, specializing in US capital markets and financial sector research. He covers a range of financial services companies, particularly in the capital markets and consumer services segments, with a focus on detailed analytical research for institutional investors. Having joined Autonomous Research in 2019, he is based in New York and plays a key role in the firm’s US research operations. Fellinger’s professional credentials, performance track record, and specific company coverage are not publicly disclosed, but his expertise has contributed to the team's consistent delivery of high-quality market intelligence for clients.

    Richard Fellinger's questions to Tradeweb Markets (TW) leadership

    Richard Fellinger's questions to Tradeweb Markets (TW) leadership • Q1 2025

    Question

    Richard Fellinger asked about capital allocation, specifically how market uncertainty affects the appetite for M&A and at what point the company might consider more opportunistic share buybacks.

    Answer

    CEO William Hult reiterated that M&A remains the preferred use of cash, with a focus on cultural fit and under-resourced technology networks. CFO Sara Furber confirmed the capital allocation waterfall remains organic growth, then M&A, followed by share repurchases and dividends. She stated that while the company's strong balance sheet allows it to be nimble and opportunistic, any deal must be financially disciplined and accretive to revenue and/or earnings growth. Share repurchases beyond offsetting dilution would be a function of accretion analysis.

    Ask Fintool Equity Research AI

    Richard Fellinger's questions to Tradeweb Markets (TW) leadership • Q3 2024

    Question

    Richard Fellinger of Autonomous Research inquired about the longer-term outlook for expense growth and adjusted EBITDA margin expansion over the next few years.

    Answer

    CFO Sara Furber explained that expense growth is variable and depends on the revenue environment and strategic investments. She noted that while they expect to continue expanding margins, the expansion in 2025 might be more muted due to specific factors. These include approximately $35 million in incremental expenses from the full-year impact of the ICD acquisition and about $7 million in higher occupancy costs in the second half of 2025 due to their new headquarters.

    Ask Fintool Equity Research AI